Search

everythinglearnresearchcommunity

for

Search:↓

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

New treatments for sudden hair loss include oral medications and a special laser, both showing promise in hair regrowth.

EGFR-targeting cancer drugs can cause skin rashes and other side effects.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Erlotinib can cause hair loss as a side effect.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

The document concludes that oral finasteride and topical minoxidil are effective for genetic hair loss, while other treatments for different types of hair loss show promise but need more research.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Nilotinib can cause skin issues like red bumps and hair loss.

Blocking certain immune signals can reduce skin damage from radiation therapy.

Ruxolitinib treatment may cause eyelash growth.

A woman's hair turned white after taking a cancer drug called dasatinib.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Several new treatments for different types of hair loss show promise in improving patient quality of life.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Nilotinib can cause generalized keratosis pilaris.